Squarepoint Ops LLC Cuts Stock Position in Altimmune, Inc. (NASDAQ:ALT)

Squarepoint Ops LLC lessened its holdings in Altimmune, Inc. (NASDAQ:ALT) by 76.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 14,706 shares of the company’s stock after selling 46,982 shares during the period. Squarepoint Ops LLC’s holdings in Altimmune were worth $106,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Two Sigma Investments LP grew its position in Altimmune by 33.2% in the fourth quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock worth $4,364,000 after acquiring an additional 151,001 shares in the last quarter. Rafferty Asset Management LLC grew its position in Altimmune by 1.3% in the fourth quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company’s stock worth $1,137,000 after acquiring an additional 1,964 shares in the last quarter. ProShare Advisors LLC grew its position in Altimmune by 74.1% in the fourth quarter. ProShare Advisors LLC now owns 23,371 shares of the company’s stock worth $169,000 after acquiring an additional 9,950 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Altimmune by 22.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,899 shares of the company’s stock worth $194,000 after acquiring an additional 4,851 shares in the last quarter. Finally, Millennium Management LLC grew its position in Altimmune by 139.8% in the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company’s stock worth $2,492,000 after acquiring an additional 201,484 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALT. Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Thursday, April 3rd. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus target price of $20.20.

Altimmune Stock Up 5.9%

Shares of ALT stock opened at $5.95 on Tuesday. Altimmune, Inc. has a 52-week low of $3.55 and a 52-week high of $11.16. The stock has a market cap of $482.59 million, a PE ratio of -3.84 and a beta of 0.58. The business has a 50-day simple moving average of $5.13 and a 200-day simple moving average of $6.31.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. During the same quarter in the prior year, the business earned ($0.34) earnings per share. Sell-side analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Gregory L. Weaver purchased 10,000 shares of Altimmune stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the transaction, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.